Ariel Precision Medicine
- Biotech or pharma, therapeutic R&D
- Digital health
- IT, information
- Other products or services
- Diagnostics
Ariel is developing APM-176, a Phase 2 ready NCE which potentiates CFTR (both mutated and wild-type) targeting patients with CFTR mediated chronic conditions such as Chronic rhinosinusitis (CRS), pancreatitis, bronchiectasis and biliary diseases. Our AI fueled genetic segmentation tool enriches clinical trials with appropriate patients, decreasing the trial size requirements while increasing the likelihood of success. APM176 significant improves ion Chanel activity in DelF508 CFTR which represents 70% of CFTR mutations.
Address
PittsburghPennsylvania
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}